Microscale 3D Liver Bioreactor for In Vitro Hepatotoxicity Testing under Perfusion Conditions
Journal Article
·
· Bioengineering
- Charité – Universitätsmedizin Berlin (Germany). Berlin-Brandenburg Center for Regenerative Therapies (BCRT)
- Leipzig Univ. (Germany). Dept. of Hepatobiliary Surgery and Visceral Transplantation
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
- StemCell Systems GmbH, Berlin (Germany)
The accurate prediction of hepatotoxicity demands validated human in vitro models that can close the gap between preclinical animal studies and clinical trials. In this study we investigated the response of primary human liver cells to toxic drug exposure in a perfused microscale 3D liver bioreactor. The cellularized bioreactors were treated with 5, 10, or 30 mM acetaminophen (APAP) used as a reference substance. Lactate production significantly decreased upon treatment with 30 mM APAP (p < 0.05) and ammonia release significantly increased in bioreactors treated with 10 or 30 mM APAP (p < 0.0001), indicating APAP-induced dose-dependent toxicity. The release of prostaglandin E2 showed a significant increase at 30 mM APAP (p < 0.05), suggesting an inflammatory reaction towards enhanced cellular stress. The expression of genes involved in drug metabolism, antioxidant reactions, urea synthesis, and apoptosis was differentially influenced by APAP exposure. Histological examinations revealed that primary human liver cells in untreated control bioreactors were reorganized in tissue-like cell aggregates. These aggregates were partly disintegrated upon APAP treatment, lacking expression of hepatocyte-specific proteins and transporters. In conclusion, our results validate the suitability of the microscale 3D liver bioreactor to detect hepatotoxic effects of drugs in vitro under perfusion conditions.
- Research Organization:
- Charité – Universitätsmedizin Berlin (Germany); Leipzig Univ. (Germany); Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
- Sponsoring Organization:
- Defense Threat Reduction Agency (DTRA) (United States); Federal Ministry of Education and Research (BMBF) (Germany); USDOE
- Grant/Contract Number:
- AC52-06NA25396
- OSTI ID:
- 1479987
- Report Number(s):
- LA-UR--18-21816
- Journal Information:
- Bioengineering, Journal Name: Bioengineering Journal Issue: 1 Vol. 5; ISSN 2306-5354
- Publisher:
- MDPICopyright Statement
- Country of Publication:
- United States
- Language:
- English
Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system
|
text | January 2019 |
Conceptual Design of Micro-Bioreactors and Organ-on-Chips for Studies of Cell Cultures
|
journal | July 2018 |
Advances in Micro-Bioreactor Design for Organ Cell Studies
|
journal | August 2018 |
Human-Derived Organ-on-a-Chip for Personalized Drug Development
|
journal | April 2019 |
Similar Records
Increased hepatotoxicity of acetaminophen in Hsp70i knockout mice
A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen
Mitochondrial protein adducts formation and mitochondrial dysfunction during N-acetyl-m-aminophenol (AMAP)-induced hepatotoxicity in primary human hepatocytes
Journal Article
·
Sat Jan 14 23:00:00 EST 2006
· Toxicology and Applied Pharmacology
·
OSTI ID:20783414
A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen
Journal Article
·
Sun Jan 31 23:00:00 EST 2016
· Toxicology and Applied Pharmacology
·
OSTI ID:22687888
Mitochondrial protein adducts formation and mitochondrial dysfunction during N-acetyl-m-aminophenol (AMAP)-induced hepatotoxicity in primary human hepatocytes
Journal Article
·
Mon Nov 30 23:00:00 EST 2015
· Toxicology and Applied Pharmacology
·
OSTI ID:22687827